Covid-19 roundup: Cure­Vac push­es ahead for vac­cine au­tho­riza­tion de­spite fail­ing to hit 50% ef­fi­ca­cy thresh­old

4 years ago
Coronavirus

Pfiz­er bets on Spero can­di­date, wad­ing deep­er along­side GSK and Roche in­to aban­doned an­tibi­ot­ic mar­ket

4 years ago
R&D

An­oth­er re­pur­posed drug bites the dust in Covid-19 as An­gion bails on or­gan dam­age drug ef­fort

4 years ago
R&D
Coronavirus

From base­ment lab to Wall Street: Ab­sci looks to bring its 'pro­tein print­ing' plat­form pub­lic

4 years ago
Financing

Ac­tivist El­liott be­gins its long-await­ed at­tack on CEO Em­ma Walm­s­ley and a Glax­o­SmithK­line that has 'lost its way'

4 years ago
Financing
Deals

Apel­lis, Beam team up to test base edit­ing against the broad field of com­ple­ment dis­or­ders

4 years ago
Deals
Cell/Gene Tx

3 gene ther­a­py com­pa­nies se­cure VC mon­ey; No­valis clos­es near­ly $30 mil­lion fund

4 years ago
News Briefing

For­mer Viela CEO Bing Yao finds his next gig — bring­ing Chi­nese R&D in­no­va­tion state­side

4 years ago
Startups
China

ICER finds Bio­gen’s new ex­or­bi­tant­ly priced Alzheimer’s drug doesn’t match even an op­ti­mistic view of po­ten­tial ...

4 years ago
Pharma

Say good­bye to plants: Syn­bio play­er An­theia earns new back­ers in quest to re­design flo­ra-de­rived med­i­cine ...

4 years ago
Financing

Joe Jimenez and Mark Fish­man sign up their 5th drug can­di­date — and they have an­oth­er big tar­get in their ...

4 years ago
Deals
R&D

A dry-pow­der lung dis­ease drug and next-gen an­tibi­otics: Two biotechs and an $880M slate of SPACs land on Wall Street ...

4 years ago
Financing

Pa­tient ex­pe­ri­ence da­ta in reg­u­la­to­ry de­ci­sions: Ques­tions abound in first FDA re­port

4 years ago
Pharma
FDA+

Gen­Sight's gene ther­a­py mys­tery con­tin­ues, as pa­tients im­prove in an­oth­er failed tri­al

4 years ago
R&D
Cell/Gene Tx

Covid-19 roundup: GSK and Vir reach sotro­vimab sup­ply agree­ment in Sin­ga­pore; J&J vac­cine shows var­ied suc­cess ...

4 years ago
Coronavirus

Bask­ing in lime­light of a CRISPR break­through, In­tel­lia bags $600M cash raise as shares soar to all-time high

4 years ago
Financing

Ab­b­Vie says Rin­voq shines again as main­te­nance ther­a­py for ul­cer­a­tive col­i­tis — but safe­ty con­cerns still loom over ...

4 years ago
R&D
Pharma

Is 9 years too long to run a con­fir­ma­to­ry study for a drug like ad­u­canum­ab? In Sarep­ta’s case, it isn’t enough ...

4 years ago
Bioregnum
R&D

Cerev­el's stock rock­ets up on re­lease of ear­ly da­ta in schiz­o­phre­nia, fol­lowed by an of­fer­ing

4 years ago
R&D

An In­di­ana CD­MO with big-name clients sets up plans for lentivi­ral pro­duc­tion site

4 years ago
Outsourcing
Manufacturing

Al­tim­mune aban­dons ship on in­tranasal Covid-19 vac­cine, re­fo­cus­ing on liv­er, obe­si­ty pro­grams af­ter tri­al flop

4 years ago
R&D
Coronavirus

Jaz­z's re­worked nar­colep­sy drug wins 7 years of or­phan ex­clu­siv­i­ty thanks to rare 'clin­i­cal su­pe­ri­or­i­ty' find­ing from ...

4 years ago
FDA+

Io­vance's TIL ther­a­py makes ear­ly head­way in lung can­cer; An­tios and Ar­bu­tus join hands on HBV com­bo treat­ment

4 years ago
News Briefing

Gilead, Fore­site take an un­known pan­dem­ic an­tivi­ral pub­lic in $250M SPAC deal

4 years ago
Financing
Deals
First page Previous page 673674675676677678679 Next page Last page
A service from the Financial Times